glp-1 drugs and menopause Weight Gain During Menopause: Solutions in the Era of GLP1-agonists Menopause and GLP-1 weight-loss drugs

They have not undergone the clinical trials required for FDA approval as a drug for human therapy

Sleep optimization Poor sleep disrupts leptin, ghrelin, and cortisol, the three hormones most directly involved in appetite regulation and fat storage

HugerthLWAndreassonATalleyNJForsbergAMKjellstrmLSchmidtPT

Glucosinolates and their breakdown derivatives (metabolites), especially isothiocyanates and indole-3-carbinol, exert a variety of biological activities that may be relevant to health promotion and disease prevention in humans (see the MIC articles on Indole-3-Carbinol and Isothiocyanates)

Pigmentation fades gradually over 48 weeks if dosing stops entirely, returning to baseline within 1216 weeks in most users

Freezing causes ice crystal formation, which mechanically disrupts peptide structure and concentrates solutes in unfrozen regions (the "freeze concentration" effect)